Cancer types
  • Urology
Title of study
Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy
Version Number
Approval Date 
3.0, 15 April 2020
Short Title
ADOPT
Study site
Principle Investigator
Shafak Aluwini (UMC Groningen)
Investigator Maastro
Dr. B. Vanneste
Sponsor
UMCG department of Radiation Oncology
Trial registry
Objectives 

To test the hypothesis that the addition of ADT to metastasis-directed radiotherapy (MDRT)in well-selected PCa patients with oligometastatic disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.

Primary Endpoint 

The 2.5-year metastases progression-free survival.

Secondary Endpoints 

Acute and late toxicity, quality of life (QoL), biochemicalprogression-free survival and overall survival.